

Name : Mr. GURDEEP SINGH

Age: 38 Y

Sex: M

: 38 Y

OP Number: SCHIOPV24145

Bill No :SCHI-OCR-8863

Date : 20.12.2023 08:43

UHID:CIND.0000071365

Address: 8179 VASANT KUNJ

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT


no	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2	2D ECHO - PAN INDIA - FY2324
	I URINE GLUCOSE(FASTING)	
	2 GAMMA GLUTAMYL TRANFERASE (GGT)	
	PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL)	
	HbA1c, GLYCATED HEMOGLOBIN	
	5 2 D ECHO .	
(6 ALKALINE PHOSPHATASE - SERUM/PLASMA 🜙	
	7 LIVER FUNCTION TEST (LFT)	
	8 X-RAY CHEST PA	
	9 GLUCOSE, FASTING	j
10	0 HEMOGRAM + PERIPHERAL SMEAR	
1	ENT CONSULTATION DLM (Ansenn	
1	2 FITNESS BY GENERAL PHYSICIAN	
1.	DIET CONSULTATION	
1	4 COMPLETE URINE EXAMINATION —	
1.	5 URINE GLUCOSE(POST PRANDIAL)	
10	6 PERIPHERAL SMEAR	
1	7 ECG	
1	8 BLOOD GROUP ABO AND RH FACTOR	
15	9 VITAMIN B12	
- 2	O LIPID PROFILE	
2	BODY MASS INDEX (BMI)	
2:	2 OPTHAL BY GENERAL PHYSICIAN	
2.	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
2.	4 ULTRASOUND - WHOLE ABDOMEN	
2.	5 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
. 2	6 DENTAL CONSULTATION V	· · · · · · · · · · · · · · · · · · ·
2	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) $\frac{7!}{37} - \frac{11!}{32}$	
2	8 VITAMIN D - 25 HYDROXY (D2+D3)	

a Thomas Show HING

Height 120, 8

Neight 26, 80

Pulse: Show after



भारतीय विशिष्ट पहुंचान प्राधिकरण Unique Identification Authority of India

Address: S/O Labh Singh, House No. HE-30, Phase 5, S.A.S.Nagar (Mohall), S.A.S Nagar (Mohall), Punjab, 160059



9436 0077 6593







PHC Desk

From:

Corporate Apollo Clinic <corporate@apolloclinic.com>

Sent:

19 December 2023 18:06

To:

'Customer Care : Mediwheel : New Delhi'

Cc:

Wellness: Mediwheel: New Delhi; Network: Mediwheel: New Delhi; deepak;

Basavanagudi Apolloclinic; phc Klc

Subject:

RE: Health Check-up Booking No. 3 (Annual Blue)

Namaste Team,

Greetings from Apollo clinics,

With regards to the below request, below appointments are confirmed at 9:00 AM on Requested Dates.

Thanks & Regards,

Sanjeev kumar | Apollo Clinics | Pan India Toll No: 1860 500 7788 | Contact E-

Mail: corporate@apolloclinic.com | www.apolloclinic.com |

From: Customer Care: Mediwheel: New Delhi < customercare@mediwheel.in>

Sent: 19 December 2023 13:50

To: Corporate Apollo Clinic <corporate@apolloclinic.com>

Cc: Wellness: Mediwheel: New Delhi < wellness@mediwheel.in>; Network: Mediwheel: New Delhi

<network@mediwheel.in>; deepak <deepak.c@apolloclinic.com>

Subject: Health Check-up Booking No. 3 (Annual Blue)

Dear Team,

Please note the following Health Check-up Booking and confirm the same.

S.			Booking			1
No.	Company Name	PACKAGE NAME	lD.	EMP-NAME	AGE	Ti.
		ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL				_
	Arcofemi/Mediwheel	CHECK ADVANCED HC MALE -2D ECHO - PAN INDIA -				
1	/MALE/FEMALE	FY2324		Gurdeep Singh	381	V
	Arcofemi/Mediwheel	ARCOFEMI - MEDIWHEEL - FULL BODY STANDARD		VISHWANATH N		_
2	/MALE/FEMALE	PLUS MALE - PAN INDIA - FY2324		KARANTH	59 N	V
	Arcofemi/Mediwheel	ARCOFEMI - MEDIWHEEL - FULL BODY HC STARTER			F	-e
3	/MALE/FEMALE	FEMALE - PAN INDIA - FY2324		Shanthala U R	57 e	ž

Thanks & Regards



Arcofemi Health Care Ltd. | F-701 A, Lado Sarai, Mehrauli | New Delhi – 110 030 Ph No. 011-41195959

Email: customercare@mediwheel.in; | Web: www.mediwheel.in





Apollo Clinic

CONSENT FORM

Patient Name: Crurdeel Suylu Age: 384 M UHID Number: 1365 Company Name: Arcofem i
IMT/MES/ME GURDEEP SINGH Employee of UNION BANK OF INDIA
(Company) Want to inform you that I am not interested in getting
Tests done which is a part of my routine health check package.
And I claim the above statement in my full consciousness.
Patient Signature: Goodward Date: 20/12/2023



CERTIFICATE OF MEDICAL FITNESS

Me	dically Fit
Fit	with restrictions/recommendations
	ough following restrictions have been revealed, in my opinion, these are impediments to the job.
1	
2	
3	
Hoy bee	wever the employee should follow the advice/medication that has n communicated to him/her.
Rev	riew after
	rently Unfit. iew after recommended
Rev	

Medical Officer
The Apollo Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

NAME:- D A DO: 6	- AMARAN
AGE/CENDER Chile & Mah	UHID No: CIND. 0000071365
DANIEL DE SEARCE MAL	RECEIPT No:-
PANEL: Macdemi Meduch as	EXAMINED ON: - 28 12 12
	7 28 (12/2)
0.1	
Chief	
Chief Complaints:	
No 20.	yica Ho
	y ce 10
Past History:	The state of the s
DM : Nil Hypertension : Nil	CVA : Níi
CAD : Nil	Cancer: NIT
	Other : Nit
Personal History:	
Alcohol : MI	
Smoking : Nil	Activity : Active
Family History: DM UT	Allergies : Nil
General Physical Examination:	
Height 170 : cms	
Weight O W	Pulse Sly bpm BP bpm
Part of our :	128765 mining
Rest of examination was within normal limits.	100/80
Systemic Examination:	
CVS : Normal	
Respiratory system · Normal	Section 1980 A Company Control
Abdominal system : Normal	
CNS : Normal Others : Normal	
Others : Normal	

Dr. Lalit Mohan Parashar

MS (ENT) Ear, Nose, Throat Specialist and Head & Neck Surgeon MCI: 4774/85

Specialists in Surgery

For Appointmnt: +91 1140465555

Mob.: +91 9910995018

EARS - Bh Tm (N)

VOICE, SPIZZEN NO NIZANA

1 REVIEW CT. SCM

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



20 Dec/ 2023

Mer. Gweder Sings 38 Y/Male.

c/c! Regulare Dental Check- 4p.

M/H: N.R.

PDH! - Exteraction of left lower voisdom tooth

OE!- Stains peusen

Calculus +.

Arnised. Sealing Found Perophylamin

Oeotho Scan 3D fou Alignus

p

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

Specialists in Surgery Y raison

Adu- Dandelle - Hy Ege Obb

Cappine sant claris

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.

CIN - U85100TG2009PTC099414 **Regd. Office:** 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040-4904 7777 | www.apollohl.com





Patient Name

: Mr. GURDEEP SINGH

UHID Conducted By: : CIND.0000071365

: Dr. MUKESH K GUPTA : SELF

Age

OP Visit No

Conducted Date

: 38 Y/M

: SCHIOPV24145 : 20-12-2023 15:05

Referred By

MITRAL VALVE

Morphology $AML-\underline{Normal}/Thickening/Calcification/Flutter/Vegetation/Prolapse/SAM/Doming.$

PML-Normal/Thickening/Calcification/Prolapse/Paradoxical motion/Fixed.

Doppler

Subvalvular deformity Present/Absent. Normal/Abnormal

Present/Absent

Score :_ E=A

EDG ___mmHg MDG_ _mmHg RR Interval MVA

Mitral Regurgitation

Mitral Stenosis

Absent/Trivial/Mild/Moderate/Severe.

TRICUSPID VALVE

Morphology Doppler

Normal/Atresia/Thickening/Calcification/Prolapse/Vegetation/Doming.

Normal/Abnormal

Tricuspid stenosis

Present/Absent

RR interval__

____mmHg Tricuspid regurgitation: MDG____mmHg

Absent/Trivial/Mild/Moderate/Severe Fragmented signals

Velocity__ msec. Pred. RVSP=RAP+_ mmHg

PULMONARY VALVE

Morphology

Normal/Atresia/Thickening/Doming/Vegetation.

Normal/Abnormal. Doppler

Pulmonary stenosis

Present/Absent

Level

___mmHg PSG_ Pulmonary annulus___mm

Pulmonary regurgitation

Early diastolic gradient_ _mmHg.

Absent/Trivial/Mild/Moderate/Severe End diastolic gradient_mmHg

AORTIC VALVE

Morphology

Normal/Thickening/Calcification/Restricted opening/Flutter/Vegetation

No. of cusps 1/2/3/4

Doppler

Normal/Abnormal

Aortic stenosis

Present/Absent

Aortic annulus_

Aortic regurgitation

PSG____mmHg Absent/Trivial/Mild/Moderate/Severe.

Measureme	nts	Normal Values	Measurements		Normal values
Aorta	3.0	(2.0 - 3.7cm)	LA es	3.4	(1.9 - 4.0cm)
LV es	3.0	(2.2 - 4.0 cm)	LV ed	4.5	(3.7 - 5.6cm)
IVS ed	1.0	(0.6 - 1.1 cm)	PW (LV)	0.9	(0.6 - 1.1cm)
RV ed		(0.7 - 2.6 cm)	RV Anterior wall		(upto 5 mm)
LVVd (ml)			LVVs (ml)		
EF	58%	(54%-76%)	IVS motion	Nori	mal/Flat/Paradoxical

CHAMBERS:

Contraction Normal/Reduced

Regional wall motion abnormality

Absent

Normal/Enlarged/Clear/Thrombus Normal/Enlarged/Clear/Thrombus

Normal/Enlarged/Clear/Thrombus/Hypertrophy

RV

Normal/Enlarged/Clear/Thrombus

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



PERICARDIUM

- COMMENTS & SUMMARY
 v Normal LV systolic function
 v No RWMA, LVEF=58%
- v Grade I LVDD
- v No AR, PR, MR & TR
- v No I/C clot or mass
- v Good RV function v Normal pericardium
- v No pericardial effusion



Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

Apollo Specialty Hospital Pvt. Ltd.



NAME:	GURDEEP SINGH	AGE/SEX:	38	YRS./M
UHID:	71365	×		
REF BY:	APOLLO SPECTRA	DATE:-	20.12.	2023

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size, and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Prostate: normal in size, weight 16.1 Gms. It is normal in echotexture with no breech in the capsule.

No free fluid seen.

IMPRESSION: FATTY CHANGES IN LIVER GRADE II

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRA
Consultant Radiologist
Dr. MONICA CHHABRA

Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



DIGITAL X-RAY REPORT

NAME: GURDEEP SINGH	DATE: 20.12.2023
UHID NO: 71365	AGE: 38YRS/ SEX: M

X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. MONICA CHHABRA Consultant Radiologist

Dr. MONICA CHHABRA Consultant Radiologist DMC No. 18744 Apollo Spectra Hospitals New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365 Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM Received : 20/Dec/2023 09:42AM

Received : 20/Dec/2023 09:42AM Reported : 20/Dec/2023 11:09AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Page 1 of 14







Age/Gender : 38 Y 5 M 14 D/M
UHID/MR No : CIND.0000071365

UHID/MR No : CIND.0000071365 Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG | Collected : 20/Dec/2023 08:59AM | Received : 20/Dec/2023 09:42AM | Reported : 20/Dec/2023 11:09AM |

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	14.1	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV	43.60	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.17	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	84.4	fL	83-101	Calculated
MCH	27.2	pg	27-32	Calculated
MCHC	32.2	g/dL	31.5-34.5	Calculated
R.D.W	14.3	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,490	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	62.1	%	40-80	Electrical Impedance
LYMPHOCYTES	25.6	%	20-40	Electrical Impedance
EOSINOPHILS	3.3	%	1-6	Electrical Impedance
MONOCYTES	8.5	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3409.29	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1405.44	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	181.17	Cells/cu.mm	20-500	Calculated
MONOCYTES	466.65	Cells/cu.mm	200-1000	Calculated
BASOPHILS	27.45	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	271000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOP
ERYTHROCYTE SEDIMENTATION RATE (ESR)	15	mm at the end of 1 hour	0-15	Modified Westergren

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 14





Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145 Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : FGSDFG

Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 09:42AM Reported : 20/Dec/2023 11:09AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	PLUS ANNUAL CHE	CK ADVANCED	HC MALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR	, WHOLE BLOOD EDTA	
BLOOD GROUP TYPE	0	Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE	Forward & Reverse Grouping with Slide/Tube Agglutination

Page 3 of 14







Patient Name

: Mr.GURDEEP SINGH

Age/Gender

: 38 Y 5 M 14 D/M

UHID/MR No

: CIND.0000071365

Visit ID Ref Doctor : SCHIOPV24145

: Dr.SELF

Emp/Auth/TPA ID : FGSDFG

Collected

: 20/Dec/2023 11:38AM

Received Reported : 20/Dec/2023 01:04PM : 20/Dec/2023 04:51PM

Status

: Final Report

Sponsor Name

rınai Keport

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

rest Name Result Offit Blo. Ref. Range Method	Test Name Result	Unit	Bio. Ref. Range	Method
---	------------------	------	-----------------	--------

GLUCOSE, FASTING, NAF PLASMA	111	ma/dL	70-100	GOD - POD
J-2-2-3-2-, 1713-1112-, 1211-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-		····g/		

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	121	mg/dL	70-140	GOD - POD
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 14







Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 12:44PM Reported : 20/Dec/2023 02:17PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

HBA1C (GLYCATED HEMOGLOBIN), WHOLE BLOOD EDTA

, , ,				
HBA1C, GLYCATED HEMOGLOBIN	6.1	%	HPLC	
ESTIMATED AVERAGE GLUCOSE (eAG)	128	mg/dL	Calculated	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)





Method

Patient Name : Mr.GURDEEP SINGH

Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Test Name

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM Received : 20/Dec/2023 09:42AM

Reported : 20/Dec/2023 11:09AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

Bio. Ref. Range

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Result

Unit

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	278	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	265	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	45	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	233	mg/dL	<130	Calculated
LDL CHOLESTEROL	180	mg/dL	<100	Calculated
VLDL CHOLESTEROL	53	mg/dL	<30	Calculated
CHOL / HDL RATIO	6.18		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
L.D.L.	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- **6.** VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 14







Method

Patient Name : Mr.GURDEEP SINGH

Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Test Name

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM Received : 20/Dec/2023 09:42AM

Reported : 20/Dec/2023 11:09AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

Bio. Ref. Range

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Unit

Result

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.50	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.30	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	61	U/L	<50	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	30.0	U/L	17-59	UV with P-5-P
ALKALINE PHOSPHATASE	71.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.30	g/dL	6.3-8.2	Biuret
ALBUMIN	4.80	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.50	g/dL	2.0-3.5	Calculated
A/G RATIO	1.92		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- \bullet ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- $\bullet \ To \ establish \ the \ hepatic \ origin \ correlation \ with \ GGT \ helps. \ If \ GGT \ elevated \ indicates \ hepatic \ cause \ of \ increased \ ALP.$

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 14





Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM Received : 20/Dec/2023 09:42AM

Reported : 20/Dec/2023 11:09AM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	PLUS ANNUAL CHE	CK ADVANCED	HC MALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	1.10	mg/dL	0.66-1.25	Creatinine amidohydrolase	
UREA	26.60	mg/dL	19-43	Urease	
BLOOD UREA NITROGEN	12.4	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	7.80	mg/dL	3.5-8.5	Uricase	
CALCIUM	8.30	mg/dL	8.4 - 10.2	Arsenazo-III	
PHOSPHORUS, INORGANIC	3.10	mg/dL	2.5-4.5	PMA Phenol	
SODIUM	143	mmol/L	135-145	Direct ISE	
POTASSIUM	3.9	mmol/L	3.5-5.1	Direct ISE	
CHLORIDE	103	mmol/L	98 - 107	Direct ISE	

Page 8 of 14







Nitoranalide

Patient Name : Mr.GURDEEP SINGH

Age/Gender : 38 Y 5 M 14 D/M UHID/MR No : CIND.0000071365

UHID/MR No : CIND.0000071365 Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG

(GGT), SERUM

| Collected : 20/Dec/2023 08:59AM | Received : 20/Dec/2023 09:42AM | Reported : 20/Dec/2023 10:07AM |

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324						
Test Name	Result	Unit	Bio. Ref. Range	Method		
ALKALINE PHOSPHATASE, SERUM	71.00	U/L	38-126	p-nitrophenyl phosphate		
GAMMA GLUTAMYL TRANSPEPTIDASE 47.00 U/L 15-73 Glyclyclycine						

Page 9 of 14





Ref Doctor





Method

Patient Name : Mr.GURDEEP SINGH

: Dr.SELF

Test Name

Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Emp/Auth/TPA ID : FGSDFG

Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 01:11PM

Reported : 20/Dec/2023 02:50PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

Bio. Ref. Range

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Result

Unit

THYROID PROFILE TOTAL (T3, T4, TSH) , SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	0.65	ng/mL	0.7-2.04	CLIA		
THYROXINE (T4, TOTAL)	8.95	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	0.770	μIU/mL	0.34-5.60	CLIA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 14









Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 01:11PM

Reported : 20/Dec/2023 02:19PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

VITAMIN D (25 - OH VITAMIN D) , SERU	6.53	ng/mL	30-100	CLIA	
--------------------------------------	------	-------	--------	------	--

Kindly correlate clinically.

Comment:

BIOLOGICAL REFERENCE RANGES

VITAMIN D STATUS	VITAMIN D 25 HYDROXY (ng/mL)
DEFICIENCY	<10
INSUFFICIENCY	10 – 30
SUFFICIENCY	30 – 100
TOXICITY	>100

The biological function of Vitamin D is to maintain normal levels of calcium and phosphorus absorption. 25-Hydroxy vitamin D is the storage form of vitamin D. Vitamin D assists in maintaining bone health by facilitating calcium absorption. Vitamin D deficiency can also cause osteomalacia, which frequently affects elderly patients.

Vitamin D Total levels are composed of two components namely 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 both of which are converted into active forms. Vitamin D2 level corresponds with the exogenous dietary intake of Vitamin D rich foods as well as supplements. Vitamin D3 level corresponds with endogenous production as well as exogenous diet and supplements.

Vitamin D from sunshine on the skin or from dietary intake is converted predominantly by the liver into 25-hydroxy vitamin D, which has a long half-life and is stored in the adipose tissue. The metabolically active form of vitamin D, 1,25-di-hydroxy vitamin D, which has a short life, is then synthesized in the kidney as needed from circulating 25-hydroxy vitamin D. The reference interval of greater than 30 ng/mL is a target value established by the Endocrine Society.

Decreased Levels:

Inadequate exposure to sunlight.

Dietary deficiency.

Vitamin D malabsorption.

Severe Hepatocellular disease.

Drugs like Anticonvulsants.

Nephrotic syndrome.

Increased levels:

Vitamin D intoxication.

Page 11 of 14







Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

: Dr.SELF

Visit ID : SCHIOPV24145

Emp/Auth/TPA ID : FGSDFG

Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 01:11PM Reported : 20/Dec/2023 02:25PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

VITAMIN B12 . SERUM	172	pg/mL	107.2-653.3	CLIA
VITAIVIIN DIZ, SERUIVI	172	pg/IIIL	107.2-653.3	CLIA

Comment:

Ref Doctor

- Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes.
- The most common cause of deficiency is malabsorption either due to atrophy of gastric mucosa or diseases of terminal ileum.

 Patients taking vitamin B12 supplementation may have misleading results.
- A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12 .
- The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations are normal.
- Increased levels can be seen in Chronic renal failure, Congestive heart failure, Leukemias, Polycythemia vera, Liver disease etc.

TOTAL PROSTATIC SPECIFIC ANTIGEN	0.390	ng/mL	0-4	CLIA
(tPSA), SERUM				





Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM Received : 20/Dec/2023 10:02AM

Reported : 20/Dec/2023 11:09AM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY	PLUS ANNUAL CHE	CK ADVANCED	HC MALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

COMPLETE URINE EXAMINATION (CUE)	, URINE			
PHYSICAL EXAMINATION				
COLOUR	YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.030		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	POSITIVE (+)		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MOUN	T AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-2	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 13 of 14







Age/Gender : 38 Y 5 M 14 D/M

UHID/MR No : CIND.0000071365

Visit ID : SCHIOPV24145

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : FGSDFG Collected : 20/Dec/2023 08:59AM

Received : 20/Dec/2023 10:02AM Reported : 20/Dec/2023 11:09AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick
LIDINE CLUCOSE/EASTING)	NECATIVE	NECATIVE	Dinetick

*** End Of Report ***

Dr. Tanish Mandal

Dr. SHWETA GUPTA M.B.B.S,M.D(Pathology)
MBBS,MD (Pathology) Consultant Pathologist
Consultant Pathology

Dr Nidhi Sachdev M.B.B.S,MD(Pathology)

Consultant Pathologist

Page 14 of 14

